Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study

Zhu, DL; Gan, SL; Liu, Y; Ma, JH; Dong, XL; Song, WH; Zeng, JE; Wang, GX; Zhao, WJ; Zhang, Q; Li, YK; Fang, H; Lv, XF; Shi, YQ; Tian, HM; Ji, LN; Gao, X; Zhang, LH; Bao, YQ; Lei, MX; Li, L; Zeng, LY; Li, XY; Hou, XH; Zhao, Y; Hu, TX; Ge, XY; Zhao, GY

Chen, L (reprint author), Hua Med, Shanghai 201203, Peoples R China.

LANCET DIABETES & ENDOCRINOLOGY, 2018; 6 (8): 627